 Claudia Amura
Concepts (329)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Buprenorphine | 2 | 2022 | 138 | 0.760 |
Why?
| | Cysts | 4 | 2009 | 93 | 0.700 |
Why?
| | Opioid-Related Disorders | 2 | 2022 | 422 | 0.590 |
Why?
| | Liver Diseases | 3 | 2009 | 263 | 0.550 |
Why?
| | Reperfusion Injury | 3 | 2013 | 254 | 0.510 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2009 | 209 | 0.480 |
Why?
| | Kidney Tubules | 2 | 2012 | 107 | 0.470 |
Why?
| | Macrophage Activation | 3 | 1998 | 165 | 0.430 |
Why?
| | Cyst Fluid | 3 | 2009 | 27 | 0.400 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 112 | 0.390 |
Why?
| | Complement Factor B | 1 | 2012 | 100 | 0.390 |
Why?
| | TRPP Cation Channels | 3 | 2009 | 63 | 0.370 |
Why?
| | Cytokines | 7 | 2012 | 1853 | 0.360 |
Why?
| | Complement Activation | 2 | 2012 | 343 | 0.350 |
Why?
| | Liver | 3 | 2008 | 1690 | 0.350 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 285 | 0.340 |
Why?
| | Acute-Phase Proteins | 2 | 1998 | 64 | 0.310 |
Why?
| | Receptors, Interleukin-8B | 1 | 2008 | 23 | 0.300 |
Why?
| | Lipopolysaccharides | 5 | 1999 | 826 | 0.290 |
Why?
| | Pyrroles | 2 | 2009 | 185 | 0.280 |
Why?
| | Interleukin-8 | 1 | 2008 | 241 | 0.280 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 104 | 0.280 |
Why?
| | Cell Proliferation | 3 | 2009 | 2194 | 0.280 |
Why?
| | Epithelial Cells | 5 | 2012 | 961 | 0.270 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2005 | 15 | 0.260 |
Why?
| | Indoles | 2 | 2009 | 309 | 0.260 |
Why?
| | Membrane Glycoproteins | 2 | 1998 | 431 | 0.260 |
Why?
| | Neurofilament Proteins | 1 | 2005 | 34 | 0.260 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 646 | 0.260 |
Why?
| | Telemedicine | 2 | 2023 | 667 | 0.250 |
Why?
| | Pluripotent Stem Cells | 1 | 2005 | 63 | 0.250 |
Why?
| | Piroxicam | 5 | 1995 | 5 | 0.230 |
Why?
| | Membrane Proteins | 3 | 2010 | 1024 | 0.210 |
Why?
| | Mice | 19 | 2013 | 15052 | 0.210 |
Why?
| | Midwifery | 1 | 2023 | 47 | 0.210 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 1998 | 1137 | 0.210 |
Why?
| | Interleukin-1 | 3 | 1995 | 971 | 0.200 |
Why?
| | Nitrous Oxide | 1 | 2022 | 15 | 0.200 |
Why?
| | Labor Pain | 1 | 2022 | 8 | 0.200 |
Why?
| | Analgesia, Obstetrical | 1 | 2022 | 17 | 0.200 |
Why?
| | Pseudomonas aeruginosa | 5 | 1995 | 301 | 0.200 |
Why?
| | Cells, Cultured | 6 | 2012 | 3914 | 0.190 |
Why?
| | Protein Kinase Inhibitors | 1 | 2007 | 790 | 0.190 |
Why?
| | Mice, Knockout | 5 | 2012 | 2604 | 0.190 |
Why?
| | Chemotaxis, Leukocyte | 4 | 1995 | 130 | 0.190 |
Why?
| | Academic Performance | 1 | 2021 | 13 | 0.190 |
Why?
| | Macrophages, Peritoneal | 2 | 1998 | 93 | 0.180 |
Why?
| | Faculty, Nursing | 1 | 2021 | 22 | 0.180 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 794 | 0.180 |
Why?
| | Crime Victims | 1 | 2022 | 80 | 0.180 |
Why?
| | Education, Nursing, Graduate | 1 | 2021 | 25 | 0.180 |
Why?
| | Intimate Partner Violence | 1 | 2022 | 69 | 0.180 |
Why?
| | Pilot Projects | 2 | 2022 | 1384 | 0.170 |
Why?
| | Students, Nursing | 1 | 2021 | 58 | 0.170 |
Why?
| | Kidney | 3 | 2013 | 1207 | 0.170 |
Why?
| | Mice, Inbred C57BL | 6 | 2012 | 4773 | 0.160 |
Why?
| | Chemotactic Factors | 3 | 1993 | 47 | 0.160 |
Why?
| | Animals | 26 | 2013 | 32104 | 0.160 |
Why?
| | Agranulocytosis | 2 | 1995 | 31 | 0.160 |
Why?
| | Asthma | 2 | 2023 | 2066 | 0.160 |
Why?
| | Lung Diseases | 2 | 1995 | 710 | 0.150 |
Why?
| | Perception | 1 | 2021 | 315 | 0.150 |
Why?
| | Altitude | 1 | 2022 | 409 | 0.150 |
Why?
| | Neurons | 1 | 2005 | 1298 | 0.150 |
Why?
| | Colorado | 3 | 2022 | 4116 | 0.150 |
Why?
| | Carrier Proteins | 2 | 1998 | 701 | 0.150 |
Why?
| | Pseudomonas Infections | 2 | 1995 | 188 | 0.140 |
Why?
| | Sepsis | 2 | 1999 | 515 | 0.130 |
Why?
| | Neutrophils | 4 | 1995 | 1172 | 0.130 |
Why?
| | Anti-Asthmatic Agents | 1 | 2019 | 350 | 0.130 |
Why?
| | Signal Transduction | 4 | 2012 | 4541 | 0.130 |
Why?
| | Glucocorticoids | 1 | 2019 | 552 | 0.120 |
Why?
| | Length of Stay | 1 | 2019 | 958 | 0.120 |
Why?
| | Mice, Inbred C3H | 4 | 1998 | 244 | 0.120 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 783 | 0.120 |
Why?
| | Promoter Regions, Genetic | 3 | 2008 | 1122 | 0.110 |
Why?
| | Endothelial Cells | 2 | 2009 | 696 | 0.110 |
Why?
| | Emergency Service, Hospital | 2 | 2023 | 1829 | 0.110 |
Why?
| | Copper | 1 | 1993 | 101 | 0.100 |
Why?
| | Immunity, Humoral | 1 | 2013 | 112 | 0.100 |
Why?
| | Health Behavior | 1 | 2018 | 708 | 0.100 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 397 | 0.100 |
Why?
| | Pediatric Obesity | 1 | 2018 | 493 | 0.090 |
Why?
| | Cell Line | 2 | 2008 | 2651 | 0.090 |
Why?
| | Superoxide Dismutase | 1 | 1993 | 332 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2009 | 88 | 0.090 |
Why?
| | Complement Inactivator Proteins | 1 | 2010 | 40 | 0.090 |
Why?
| | Humans | 18 | 2023 | 115741 | 0.090 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 68 | 0.090 |
Why?
| | Receptors, Complement | 1 | 2010 | 111 | 0.090 |
Why?
| | Complement Factor H | 1 | 2010 | 60 | 0.090 |
Why?
| | Graft Rejection | 1 | 2013 | 533 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2013 | 354 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2007 | 1870 | 0.080 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 12 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2005 | 1700 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 503 | 0.080 |
Why?
| | Female | 16 | 2023 | 60018 | 0.080 |
Why?
| | Chemokine CXCL1 | 1 | 2008 | 66 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1310 | 0.080 |
Why?
| | Cell Shape | 1 | 2008 | 54 | 0.080 |
Why?
| | Exercise | 1 | 2018 | 1609 | 0.070 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 1998 | 76 | 0.070 |
Why?
| | Injections, Intraperitoneal | 3 | 1998 | 104 | 0.070 |
Why?
| | Blood Proteins | 3 | 1998 | 238 | 0.070 |
Why?
| | Kidney Transplantation | 1 | 2013 | 558 | 0.070 |
Why?
| | Cell Polarity | 1 | 2008 | 131 | 0.070 |
Why?
| | Epithelial Sodium Channels | 1 | 2006 | 12 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2007 | 68 | 0.070 |
Why?
| | Cell Hypoxia | 1 | 2008 | 220 | 0.070 |
Why?
| | Bile Ducts | 1 | 2006 | 73 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2009 | 3580 | 0.070 |
Why?
| | Mice, Neurologic Mutants | 1 | 2005 | 19 | 0.070 |
Why?
| | Stress, Mechanical | 1 | 2008 | 462 | 0.070 |
Why?
| | Wnt4 Protein | 1 | 2005 | 17 | 0.070 |
Why?
| | Transfection | 1 | 2008 | 866 | 0.060 |
Why?
| | Luciferases | 1 | 2005 | 140 | 0.060 |
Why?
| | Pandemics | 2 | 2023 | 1335 | 0.060 |
Why?
| | Genes, Reporter | 1 | 2005 | 257 | 0.060 |
Why?
| | Embryo, Mammalian | 1 | 2005 | 214 | 0.060 |
Why?
| | Nerve Growth Factor | 1 | 2004 | 27 | 0.060 |
Why?
| | Wnt Proteins | 1 | 2005 | 135 | 0.060 |
Why?
| | Cadherins | 1 | 2005 | 175 | 0.060 |
Why?
| | Time Factors | 4 | 2007 | 6171 | 0.060 |
Why?
| | Peroxidase | 2 | 1995 | 157 | 0.060 |
Why?
| | Adult | 2 | 2022 | 30789 | 0.060 |
Why?
| | Down-Regulation | 1 | 2005 | 601 | 0.050 |
Why?
| | Certification | 1 | 2023 | 90 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2006 | 521 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 746 | 0.050 |
Why?
| | Nurse's Role | 1 | 2023 | 106 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2005 | 2574 | 0.050 |
Why?
| | Tennessee | 1 | 2022 | 42 | 0.050 |
Why?
| | Proto-Oncogene Proteins | 1 | 2005 | 609 | 0.050 |
Why?
| | Workflow | 1 | 2023 | 136 | 0.050 |
Why?
| | North Carolina | 1 | 2022 | 97 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2023 | 249 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 2751 | 0.050 |
Why?
| | Pregnancy | 2 | 2023 | 5553 | 0.050 |
Why?
| | House Calls | 1 | 2022 | 128 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 1919 | 0.040 |
Why?
| | Violence | 1 | 2022 | 202 | 0.040 |
Why?
| | Opiate Substitution Treatment | 1 | 2020 | 102 | 0.040 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1999 | 47 | 0.040 |
Why?
| | Thioglycolates | 1 | 1998 | 3 | 0.040 |
Why?
| | Galactosamine | 1 | 1998 | 3 | 0.040 |
Why?
| | Policy | 1 | 2020 | 140 | 0.040 |
Why?
| | Immune Sera | 1 | 1998 | 80 | 0.040 |
Why?
| | Monoamine Oxidase | 2 | 1975 | 27 | 0.040 |
Why?
| | Qualitative Research | 1 | 2023 | 975 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2019 | 147 | 0.040 |
Why?
| | Kinetics | 3 | 1998 | 1569 | 0.040 |
Why?
| | Blood Bactericidal Activity | 1 | 1997 | 36 | 0.040 |
Why?
| | Recombinant Proteins | 3 | 1998 | 1243 | 0.040 |
Why?
| | Leadership | 1 | 2021 | 302 | 0.040 |
Why?
| | Interleukin-12 | 1 | 1998 | 110 | 0.040 |
Why?
| | Microsomes, Liver | 2 | 1979 | 57 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 724 | 0.040 |
Why?
| | Adrenalectomy | 2 | 1975 | 80 | 0.040 |
Why?
| | Biological Transport | 1 | 1998 | 375 | 0.040 |
Why?
| | Child | 3 | 2023 | 18503 | 0.040 |
Why?
| | Urban Population | 1 | 2019 | 406 | 0.040 |
Why?
| | Enzyme Activation | 1 | 1998 | 793 | 0.030 |
Why?
| | Rats | 5 | 2004 | 5033 | 0.030 |
Why?
| | Mothers | 1 | 2022 | 666 | 0.030 |
Why?
| | Immunization | 1 | 1998 | 401 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 478 | 0.030 |
Why?
| | Interleukin-10 | 1 | 1998 | 299 | 0.030 |
Why?
| | Trypanosoma | 1 | 1975 | 7 | 0.030 |
Why?
| | Child Behavior | 1 | 2018 | 218 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 1993 | 1044 | 0.030 |
Why?
| | Benzylamine Oxidase | 1 | 1975 | 1 | 0.030 |
Why?
| | Parent-Child Relations | 1 | 2018 | 234 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2353 | 0.030 |
Why?
| | Acute-Phase Reaction | 1 | 1995 | 39 | 0.030 |
Why?
| | Quality Improvement | 1 | 2023 | 958 | 0.030 |
Why?
| | Male | 8 | 2019 | 56050 | 0.030 |
Why?
| | Mutation | 1 | 2005 | 3364 | 0.030 |
Why?
| | ADP Ribose Transferases | 1 | 1995 | 8 | 0.030 |
Why?
| | Exotoxins | 1 | 1995 | 14 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 396 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 507 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1975 | 77 | 0.030 |
Why?
| | Bacterial Toxins | 1 | 1995 | 103 | 0.030 |
Why?
| | Registries | 1 | 2022 | 1770 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 12633 | 0.030 |
Why?
| | Superoxides | 1 | 1995 | 215 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2020 | 773 | 0.030 |
Why?
| | Virulence Factors | 1 | 1995 | 139 | 0.030 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1993 | 72 | 0.030 |
Why?
| | Copper Sulfate | 1 | 1993 | 6 | 0.030 |
Why?
| | Cytochrome c Group | 1 | 1993 | 38 | 0.030 |
Why?
| | Edetic Acid | 1 | 1993 | 44 | 0.030 |
Why?
| | Lung | 3 | 1995 | 3673 | 0.030 |
Why?
| | Aggression | 1 | 1975 | 185 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2019 | 805 | 0.030 |
Why?
| | Antibody Formation | 2 | 2010 | 273 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1992 | 64 | 0.030 |
Why?
| | Algorithms | 1 | 2019 | 1500 | 0.030 |
Why?
| | Edema | 1 | 1993 | 119 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2586 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 1993 | 644 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1180 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1284 | 0.020 |
Why?
| | Adolescent | 2 | 2019 | 17922 | 0.020 |
Why?
| | Transcription Factors | 1 | 1998 | 1528 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 1971 | 0.020 |
Why?
| | Receptors, Complement 3b | 1 | 2010 | 81 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1992 | 301 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1993 | 924 | 0.020 |
Why?
| | NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 19 | 0.020 |
Why?
| | Peptidylprolyl Isomerase | 1 | 2009 | 10 | 0.020 |
Why?
| | Complement Pathway, Alternative | 1 | 2010 | 114 | 0.020 |
Why?
| | Pneumonia | 1 | 1994 | 576 | 0.020 |
Why?
| | Aniline Compounds | 1 | 1979 | 71 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4669 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2010 | 254 | 0.020 |
Why?
| | Polymerase Chain Reaction | 2 | 2004 | 1001 | 0.020 |
Why?
| | Birds | 1 | 1979 | 77 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 402 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 795 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1153 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 283 | 0.020 |
Why?
| | Protein Binding | 2 | 2010 | 1917 | 0.020 |
Why?
| | Receptors, Purinergic P2X4 | 1 | 2006 | 4 | 0.020 |
Why?
| | Receptors, Purinergic P2 | 1 | 2006 | 20 | 0.020 |
Why?
| | Amiloride | 1 | 2006 | 23 | 0.020 |
Why?
| | Ion Transport | 1 | 2006 | 55 | 0.020 |
Why?
| | Young Adult | 1 | 2022 | 10518 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1992 | 739 | 0.020 |
Why?
| | Chlorine | 1 | 2006 | 62 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 1992 | 799 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1642 | 0.020 |
Why?
| | Pentanones | 1 | 1975 | 2 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 399 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2006 | 227 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 757 | 0.020 |
Why?
| | Sodium | 1 | 2006 | 183 | 0.020 |
Why?
| | Digitoxin | 1 | 1975 | 3 | 0.020 |
Why?
| | Enzyme Induction | 1 | 1975 | 85 | 0.020 |
Why?
| | Ketones | 1 | 1975 | 44 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 3 | 1979 | 515 | 0.020 |
Why?
| | Synapsins | 1 | 2004 | 12 | 0.020 |
Why?
| | Phosphorylation | 1 | 2009 | 1571 | 0.020 |
Why?
| | PC12 Cells | 1 | 2004 | 37 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2006 | 431 | 0.010 |
Why?
| | Arginine | 1 | 1975 | 241 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 146 | 0.010 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 157 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2004 | 181 | 0.010 |
Why?
| | Antipsychotic Agents | 1 | 1976 | 183 | 0.010 |
Why?
| | Lysine | 1 | 1975 | 246 | 0.010 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 228 | 0.010 |
Why?
| | Brain | 1 | 1975 | 2373 | 0.010 |
Why?
| | Piperazines | 1 | 1975 | 314 | 0.010 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 2 | 1993 | 64 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2009 | 847 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2004 | 340 | 0.010 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2004 | 281 | 0.010 |
Why?
| | Schizophrenia | 1 | 1976 | 418 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1992 | 2207 | 0.010 |
Why?
| | Antiviral Agents | 1 | 1975 | 649 | 0.010 |
Why?
| | Proteins | 1 | 1975 | 920 | 0.010 |
Why?
| | Spermine | 1 | 1999 | 27 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 1999 | 67 | 0.010 |
Why?
| | Neutralization Tests | 1 | 1998 | 63 | 0.010 |
Why?
| | Glycine | 1 | 1999 | 156 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2004 | 1537 | 0.010 |
Why?
| | Hydroxylation | 2 | 1979 | 28 | 0.010 |
Why?
| | DNA Primers | 1 | 1998 | 514 | 0.010 |
Why?
| | Liver Glycogen | 1 | 1975 | 19 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1975 | 71 | 0.010 |
Why?
| | Ammonium Sulfate | 1 | 1975 | 12 | 0.010 |
Why?
| | Dopa Decarboxylase | 1 | 1975 | 2 | 0.010 |
Why?
| | Hydroxydopamines | 1 | 1975 | 3 | 0.010 |
Why?
| | Tubocurarine | 1 | 1975 | 4 | 0.010 |
Why?
| | Pimozide | 1 | 1975 | 4 | 0.010 |
Why?
| | Apomorphine | 1 | 1975 | 5 | 0.010 |
Why?
| | Dopamine beta-Hydroxylase | 1 | 1975 | 12 | 0.010 |
Why?
| | Acetylcholinesterase | 1 | 1975 | 8 | 0.010 |
Why?
| | Amantadine | 1 | 1975 | 7 | 0.010 |
Why?
| | Carbachol | 1 | 1975 | 21 | 0.010 |
Why?
| | Dihydroxyphenylalanine | 1 | 1975 | 8 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1975 | 19 | 0.010 |
Why?
| | Parasympatholytics | 1 | 1975 | 13 | 0.010 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 1975 | 15 | 0.010 |
Why?
| | Choline O-Acetyltransferase | 1 | 1975 | 24 | 0.010 |
Why?
| | Cholinesterase Inhibitors | 1 | 1975 | 25 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1998 | 726 | 0.010 |
Why?
| | Dogs | 1 | 1975 | 341 | 0.010 |
Why?
| | Base Sequence | 1 | 1998 | 2114 | 0.010 |
Why?
| | Culture Media | 1 | 1993 | 156 | 0.010 |
Why?
| | Nitric Oxide | 1 | 1998 | 832 | 0.010 |
Why?
| | Aerosols | 1 | 1993 | 150 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 235 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 1998 | 1265 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1993 | 608 | 0.010 |
Why?
| | Glucose | 1 | 1975 | 904 | 0.010 |
Why?
| | Phenotype | 1 | 1998 | 2839 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1992 | 1168 | 0.010 |
Why?
| | Dealkylation | 1 | 1979 | 2 | 0.010 |
Why?
| | Oxidoreductases, N-Demethylating | 1 | 1979 | 10 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1992 | 1127 | 0.010 |
Why?
| | Inactivation, Metabolic | 1 | 1979 | 11 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 1979 | 511 | 0.000 |
Why?
| | Species Specificity | 1 | 1979 | 552 | 0.000 |
Why?
| | Promazine | 1 | 1976 | 1 | 0.000 |
Why?
| | Trifluoperazine | 1 | 1976 | 4 | 0.000 |
Why?
| | Chlorpromazine | 1 | 1976 | 5 | 0.000 |
Why?
| | Basal Ganglia Diseases | 1 | 1976 | 8 | 0.000 |
Why?
| | Micrococcus | 1 | 1975 | 4 | 0.000 |
Why?
| | Digitoxigenin | 1 | 1975 | 1 | 0.000 |
Why?
| | Tyrosine Transaminase | 1 | 1975 | 2 | 0.000 |
Why?
| | Cortisone | 1 | 1975 | 9 | 0.000 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 1975 | 75 | 0.000 |
Why?
| | Chromatography, Thin Layer | 1 | 1975 | 24 | 0.000 |
Why?
| | Culture Techniques | 1 | 1975 | 80 | 0.000 |
Why?
| | Tryptophan Oxygenase | 1 | 1975 | 22 | 0.000 |
Why?
| | NADP | 1 | 1975 | 42 | 0.000 |
Why?
| | Movement Disorders | 1 | 1976 | 46 | 0.000 |
Why?
| | Muramidase | 1 | 1975 | 73 | 0.000 |
Why?
| | Tyrosine | 1 | 1975 | 219 | 0.000 |
Why?
| | Imidazoles | 1 | 1975 | 217 | 0.000 |
Why?
| | Recurrence | 1 | 1976 | 953 | 0.000 |
Why?
| | Protein Conformation | 1 | 1975 | 822 | 0.000 |
Why?
| | Binding Sites | 1 | 1975 | 1177 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1976 | 941 | 0.000 |
Why?
| | Chronic Disease | 1 | 1976 | 1598 | 0.000 |
Why?
|
|
Amura's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|